Biotech stock tumble stumps analysts

Nobody quite knows why the Nasdaq biotech index ($IBB) sank another 5.6% on Thursday. Analysts do know that the drop came the day after the index jumped 4.1%, also inexplicably, which has added to their confusion. Some have suggested pricing concerns over Gilead's ($GILD) Sovaldi may be to blame for a broader downward trend. But others say biotech stocks have simply become vastly overpriced, causing trouble in the market. Article (sub. req.)

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…